Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
June PPI Weak at -0.2%, COVID Drug Adds Promise
by Mark Vickery
June Producer Price Index headline of -0.2% was a big miss from the +0.4% consensus and the +0.4% headline for May.
Gilead Starts Testing Remdesivir Inhaled Version for Coronavirus
by Zacks Equity Research
Gilead (GILD) begins a phase I study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir for coronavirus.
Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Regeneron Initiates Studies on Experimental Coronavirus Drug
by Zacks Equity Research
Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.
Gilead Sciences (GILD) Stock Moves -0.44%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.
Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
by Zacks Equity Research
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
5 High Dividend-Yielding S&P 500 Stocks Amid Coronavirus Woes
by Swayta Shah
At a time when the coronavirus outbreak has hampered steady stream of income for many, investing in high dividend-yielding stocks can be rewarding. We have picked 5 S&P 500 stocks worth considering.
4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine
by Ritujay Ghosh
The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.
5 High Earnings Yield Stocks for a Winning Portfolio
by Zacks Equity Research
Earnings yield is very important in comparing a stock with other stocks and with fixed income securities. A stock with higher earnings yield fetches better returns.
Gilead's Coronavirus Drug Gets Conditional Approval in Europe
by Zacks Equity Research
Gilead (GILD) gets conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection by the European Commission.
Gilead's Coronavirus Drug Being Stocked by the US Government
by Zacks Equity Research
Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial
by Zacks Equity Research
Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.56, marking a -0.01% move from the previous day.
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
The Final Chapter of Chesapeake Energy Story?
by Mark Vickery
Finding difficulties in dealing with its now $10 billion in debt, fracking pioneer Chesapeake Energy (CHK) has announced it is filing for Chapter 11 bankruptcy protection.
Chesapeake Energy Files Chapter 11
by Zacks Equity Research
Chesapeake Energy Files Chapter 11
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
by Zacks Equity Research
Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Invest in the Future With Megatrend ETFs
by Neena Mishra
These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.
Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III
by Zacks Equity Research
Alexion's (ALXN) subcutaneous formulation of Ultomiris meets primary objective in a late-stage study.
Gilead to Buy 49.9% Stake in Private Biotech for $275M
by Zacks Equity Research
Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.